We are pleased to submit our manuscript entitled "Frailty in patients undergoing trans-catheter aortic valve implantation (TAVI): a protocol for a systematic review" for consideration by BMJ Open.
This is an original submission that has not been published before and that is not currently under review at any other publication outlet.
In this paper, we propose to conduct a systematic review of frailty in patients undergoing TAVI. This is significant because accurately identifying the subgroup of patients in whom TAVI is likely to be beneficial remains a priority given the economic implications of TAVI. Emerging research demonstrates that older, frail patients are at greater risk of adverse health outcomes. Thus far we are not aware of any systematic review that has determined the frequency of adverse outcomes and pooled the survival after TAVI in frail patients. We propose to include frail patients who underwent TAVI from any study that reported mortality, clinical outcomes, or health-related quality of life. To inform the overall survival of frail TAVI patients, we will digitize survival curves from included studies and pool a combined curve. We will also perform sub-group analyses, sensitivity analyses, and meta-regression to examine the robustness of results.
We believe the protocol will be of interest to readers of BMJ Open, and will complement the important work published in the journal. We think that readers interested in TAVI, frailty, prognosis of patients with aortic stenosis, and evidence-based medicine will find this work informative.
Thank you kindly in advance for your considering this manuscript. 
Methods and analysis: Methods are reported according to the Preferred Reporting Items for
Systematic reviews and Meta-analyses Protocols (PRISMA-P) 2015 checklist. We will search relevant databases to identify published, completed but unpublished and ongoing studies. We will include studies of patients with severe symptomatic aortic stenosis, diagnosed as frail, who underwent a TAVI procedure that report mortality, clinical outcomes, or health-related quality of life. Retrospective or prospective cohort studies, randomized controlled trials, and nonrandomized controlled trials will be eligible for inclusion. Two researchers will independently screen articles for inclusion, with disagreements resolved by a third reviewer. One researcher will extract data with audit by a second researcher. The risk of bias in studies will be evaluated using the Quality in Prognosis Studies tool. Meta-analysis of mortality, survival curve, the change in quality of life will be performed if appropriate. Sub-group analysis, sensitivity analysis, and meta-regression will be performed if necessary.
Ethics and dissemination:
Due to the nature of this study, no ethical issues are foreseen. We will disseminate the results of our systematic review through a peer-review journal. 
INTRODUCTION
Aortic stenosis (AS) is a significant cause of morbidity and mortality in older patients. As the ageing population continues to grow, the impact of AS on public health and health care resources are anticipated to increase. 1 In the last decade, transcatheter aortic valve implantation (TAVI) has emerged as an alternative treatment option for patients with severe symptomatic AS who are at high or intermediate risk for surgical aortic valve replacement (SAVR). 2, 3 Research on the benefits of TAVI compared to SAVR and medical management is ongoing, however it has been recognized that some patient populations fail to benefit from TAVI. 3 With increasing economic and clinical implications of TAVI, better understanding of how patient factors impact survival, functionality, complications, and quality of life remains a priority. 4 Patients referred for TAVI typically have advanced age and multiple comorbidities, and the prevalence of frailty can be as high as 63%. 5, 6 Frailty is defined as a syndrome of impaired physiological reserve and increased vulnerability to stressors. 7 When exposed to stressors, such as chronic illness and surgery, frail patients are prone to adverse events, procedural complications, prolonged recovery, functional decline, and mortality. 8 Existing evidence highlight the importance of frailty as a predictor of poor outcomes post-TAVI. [9] [10] [11] Evaluation of frailty in patients undergoing TAVI can help clinicians identify patients who would benefit most from TAVI. 4 Although multiple studies have shown the value of frailty in predicting patient outcomes after TAVI, there is still a lack of consensus on the best way to assess frailty in clinical practice, with no single standard method of measuring frailty. 3, 5 Without a clear consensus on frailty assessment practices, further review of frailty instruments and clinical outcomes of TAVI recipients becomes more important. 3 This study aims to review the operationalization of frailty instruments for TAVI recipients, and to determine the mortality, clinical outcomes, and change in quality of life in frail patients undergoing TAVI. The specific review questions will include: (1) How is frailty measured in patients undergoing TAVI? (2) What is the frequency of adverse clinical outcomes, including death, acute myocardial infraction, stroke, renal failure, pacemaker implantation, major bleeding, vascular complication, aortic regurgitation, readmission, and re-intervention, after TAVI in frail patients with aortic stenosis? (3) How does quality of life change after TAVI in frail patients with aortic stenosis?
METHODS AND ANALYSIS
The methods of this systematic review are reported according to the Preferred Reporting Items for Systematic reviews and Meta-analyses Protocols (PRISMA-P) 2015 checklist.
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Subheadings correspond to the recommended items to address in a systematic review protocol according to the checklist. 
Eligibility criteria
Participants: We will include patients with severe symptomatic aortic stenosis, diagnosed as frail, who underwent a TAVI procedure. The mean age of the study population will be restricted to 65 years and older. Since the focus of this review is on frailty rather than baseline surgical risk, we will not use baseline surgical risk as exclusion criteria. We anticipate that the majority of studies will include patients at high or intermediate surgical risk. We will include frail patients whose status had been assessed and measured prospectively using one of the following tool. [13] [14] [15] [16] We will consider both objective measures and assessments that are directly measured or self-reported. Since new frailty indices are continually being developed, we will include studies using other frailty scores that we have not yet anticipated. Individual different tools have different measures for identifying frailty and there may even be variation in the cut-off points used for the same tool across studies. 17 Therefore, we will use the criteria for frailty defined by individual studies to include patients diagnosed as frail. We will only include studies that intended to measure frailty, even if the method of frailty measurement used is not validated or well-known. If studies do not specify the method of frailty measurement, we will search the original protocol or cited references for the method used to measure frailty. Studies will be excluded if frailty was assessed without reference to a method of frailty assessment. We will not consider studies that used comorbidity or disability index alone as a marker of frailty, since these F o r p e e r r e v i e w o n l y are related but distinct conditions. 18 Studies will be excluded if baseline frailty status is measured after the TAVI procedure or if the assessment is only specifically focused on cognitive outcomes, nutritional status, mood or mental health symptoms, or social relations or support. If multiple studies originating from the same patient population are found, we will include relevant data from all studies to comprehensively report outcomes.
Intervention: We will include all forms of TAVI, regardless of procedural approach (transfemoral, transapical, transaortic, subclavian and trans-axillary approaches), types of valves (balloon-expandable valve and self-expandable system), and type of anesthesia (general, or locoregional anesthesia with conscious sedation). We will exclude studies that investigated the effects of interventions such as health services and rehabilitation programs on patients undergoing TAVI.
Outcome measures:
The primary outcome will be mortality (in-hospital mortality, all-cause mortality after 30 days and after 12 months, rate of death and time to death). Secondary outcomes will be clinical outcomes (myocardial infarction, stroke, bleeding complications, acute kidney injury, vascular complications, conduction disturbances, and new pacemaker implantation, repeat coronary or valvular intervention, neurocognitive dysfunction, delirium, length of ventilation, length of hospitalization, and readmission) and health-related quality of life. Both utility-based and psychometric measures of quality of life will be included. We anticipate most studies will report the Kansas City Cardiomyopathy Questionnaire (KCCQ), Short-Form 36 (SF-36) and the European Quality of Life Questionnaire (EQ-5D).
Types of study:
This review will include any study reporting mortality, clinical outcomes, or quality of life in patients meeting frailty criteria. We will include non-comparative cohorts of patients undergoing TAVI who have been diagnosed with frailty and comparative cohorts of frail and non-frail patients undergoing TAVI in which outcomes are reported separately for frail patients. In studies of comparative cohorts, only data in the frail cohorts will be extracted. We will include data from randomized controlled trials (RCTs) in which patients were randomized to TAVI or SAVR, if outcomes are reported separately by treatment and frailty status. Outcome data will only be abstracted from patients who underwent TAVI.
Information sources
A systematic search strategy will be employed to identify published, unpublished, and ongoing studies. We will search the online database PubMed, EMBASE, PsycINFO, Cochrane
Library, Web of Science and ClinicalTrial.gov for articles published in 2006 or later. A search of conference abstracts will be performed on conferences by the American College of Cardiology, Canadian Cardiovascular Society, American Heart Association, and European Society of Cardiology held in the last three years. In the search strategy, the publication language will not be limited as study authors have the ability to read articles published in multiple languages. We will also search the reference lists of articles and relevant reviews identified in the search for any additional studies.
At the end of study selection process, search strategies for each database will be reported, and a PRISMA flow diagram will be presented.
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Search strategy
The specific search strategies for each database will be developed by an information specialist with experience conducting systematic reviews. The research team will provide input and feedback into the development of the strategy. Keywords will include "transcatheter", "aortic valve", "frailty", "geriatric assessment", "functional assessment", "cognition", "weight 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y loss", "nutrition", and "grip strength". A draft search strategy for EMBASE is given in Table 1 .
This strategy will be adapted for other databases.
Data management
We will use Covidence online software to manage data. The title and abstract of all articles identified in the search will be uploaded to Covidence for abstract screening. Full text articles will be uploaded for further screening and reasons for exclusion will be noted at the full text review stage. All included articles will be allocated a unique study ID code and articles will be tracked throughout the data screening and extraction process. Data extraction and quality appraisal will be managed in Microsoft Excel.
Selection process
Two reviewers will independently review all abstracts identified in the initial search based on the inclusion criteria, and studies meeting the inclusion criteria will be included for full-text review. Full-text review of articles will be performed independently by two reviewers.
Disagreement will be resolved by a third reviewer.
Data collection process
We plan to use a standardized data collection form constructed in Microsoft Excel. Data will be extracted by one reviewer and independently audited by another reviewer. Disagreements will be resolved by obtaining consensus between the two reviewers. A third reviewer will be consulted for remaining disagreements, if necessary.
Data Items
The data collection form will include a list of fields given in Table 2 , consisting of study design, study setting, patient characteristics, measure of frailty, and outcomes by time point. If any information is not reported, this will be recorded in the corresponding field. If data can only 
Risk of bias in individual studies
Two reviewers will independently assess the risk of bias in individual studies using the Quality in Prognosis Studies (QUIPS) tool, which rates the studies as "high risk", "moderate risk"
or "low risk" of bias in the following domains: study population, study attrition, prognostic factor measurement, outcome measurement, study confounding, and statistical analysis and reporting. 21 For our research purpose, we will not consider the study confounding and model development strategy sections of the tool as we anticipate they will not apply to the types of studies we will be reviewing.
Dealing with missing data
We will attempt to contact study authors to obtain missing data. Reasons for missing data and how each study dealt with missing data will be discussed. Since we anticipate some patients will be lost to follow-up, we will record the "loss to follow-up" to inform risk of bias assessment in the domain of study attrition.
Data synthesis
We will summarize the frequency of clinical outcomes at each time point obtained from the studies in tabular form. Outcomes reported at each time point will be categorized. We will group results reported at similar times into pre-specified periods of interest. For example, results reported at 4 weeks and 8-weeks may be grouped with results at 6-weeks. For continuous outcomes, the mean value and standard deviation will be summarized. do not report time to event data, we will extract the number of events and the median follow-up time to calculate the event rate per 100-person years. Event rates from multiple studies will be pooled using a meta-analysis based on the Poisson distribution. For post-procedure length of hospitalization, we will pool data from multiple studies using a meta-analysis of the mean length of hospitalization.
Quality of life measures:
When two or more studies report mean quality of life using the same measures at baseline and the same follow-up time point, we will pool mean scores to analyze changes in quality of life. We will calculate the mean change in quality of life along with the standard deviation (SD), from baseline (T 1 ) to the follow-up time point (T 2 ), using the formula ୭୪ ଶି୭୪ ଵ ୗୈ ଶ . When two or more studies report mean quality of life at baseline and the . 23 We will report the standardized change scores for each time point and pool the standardized change scores from each study using random effects model. If studies measure quality of life using the SF-36, and report the mean mental component score (MCS) and the mean physical component score (PCS) separately, we will pool MCS and PCS separately.
Assessment of heterogeneity
For each meta-analysis, we will consider the studies included, to identify and characterize potential sources of heterogeneity. Differences across studies in the patient population (e.g. mean age, percentage female, and co-morbidity), may be potential sources of heterogeneity in study estimates. We will calculate the I-squared statistic to estimate the percentage of total variation across studies due to heterogeneity. Heterogeneity will be considered substantial if the I-squared value is greater than 50%.
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Sub-group analyses
We plan to perform the following sub-group analyses; however, the analysis will only be performed if we obtain sufficient data for the proposed groups. Studies will be grouped on the 
Sensitivity analyses
Meta-regression
Meta-regression will be performed to further investigate the potential source of clinical heterogeneity and to determine the influence of age, frailty (continuous variable), and quality of life measurements on outcomes if we obtain sufficient data. 25 Prevalence of frailty will be calculated by averaging the percentage of patients with its reported prevalence. The metareg function (STATA 14.0) will be used to undertake meta-regression with log-risk estimates and the standard error will be determined from 95% confidence intervals for the log-risk estimates.
Patient and Public Involvement statement:
Due to the nature of the study, patients are not involved in this project.
Discussion
While few studies have evaluated outcomes for frail patients undergoing TAVI, the increasing interest in frailty provides an opportunity to systematically review the existing evidence in order to clarify the magnitude of expected outcomes in this population.
Recently, several studies have attempted to evaluate the numerous methods of frailty assessment described in the literature. In this regard, Dent et al. reviewed the definitions and quality of more than a dozen frailty measurements used in research and clinical practice. 13 In a systematic review, Kim et al. identified 13 frailty instruments and evaluated their ability to predict negative outcomes in patients undergoing TAVI. 26 Further to this, it has been found that 29 However, while most studies aimed to improve surgical risk prediction, more research should be centered on patient outcomes and quality of life. 26 The results of this will inform clinicians, patients, and health care administrators, the best available evidence about the impact of frailty in patients undergoing TAVI. We also expect that our findings will fill certain gaps, as well as trigger further research to enhance clinical decision making and patient-important outcomes.
Ethics and dissemination
Due to the nature of the study, there are no ethical concerns informed consent required. We will disseminate the results of our systematic review through a peer-review journal. 
Competing interests:
There is no competing interests.
Funding:
There is no funding source to disclose.
Data sharing statement:
There is no additional unpublished data from the study. All data are provided in full in the main manuscript document. o n l y could be repeated strategy"; Study records:
Data management 11a Describe the mechanism(s) that will be used to manage records and data throughout the review Page 9, "Data management" Selection process 11b State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis) Page 9, "Selection process"
Data collection process 11c Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators Page 9, "Data collection process" Data items 12 List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data assumptions and simplifications Page 9, "Data items"
Outcomes and prioritization
13 List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale Page 9, "Data collection" & Page 20, " Table 2 " Risk of bias in individual studies 14 Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis Page 10, "Risk of bias in individual studies" Data synthesis 15a Describe criteria under which study data will be quantitatively synthesised Page 10, "Data synthesis" 15b If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and methods of combining data from studies, including any planned exploration of consistency (such as I 2 , Kendall's τ) Page 10, "Data synthesis" 15c Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression) Page 12, "assessment of heterogeneity", "Sub-group analyses", "sensitivity analyses", "metaregression" 15d If quantitative synthesis is not appropriate, describe the type of summary planned Meta-bias(es)
16 Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within studies)
NA
Confidence in cumulative evidence
17 Describe how the strength of the body of evidence will be assessed (such as GRADE) NA * It is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for important clarification on the items. Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the PRISMA-P Group and is distributed under a Creative Commons Attribution Licence 4.0. 
Methods and analysis: Methods are reported according to the Preferred Reporting Items for
Systematic reviews and Meta-analyses Protocols (PRISMA-P) 2015 checklist. We will search relevant databases to identify published, completed but unpublished and ongoing studies. We will include studies of patients with aortic stenosis, diagnosed as frail, who underwent a TAVI procedure that report mortality, clinical outcomes, or health-related quality of life. Retrospective or prospective cohort studies, randomized controlled trials, and non-randomized controlled trials will be eligible for inclusion. Two researchers will independently screen articles for inclusion, with disagreements resolved by a third reviewer. One researcher will extract data with audit by a second researcher. The risk of bias in studies will be evaluated using the Quality in Prognosis Studies tool. Meta-analysis of mortality, survival curve, the change in quality of life will be performed if appropriate. Sub-group analysis, sensitivity analysis, and meta-regression will be performed if necessary.
Ethics and dissemination:
Review registration number: PROSPERO 2018 CRD42018090597
Strengths and limitations of this study:
• This review is anticipated to be the first to determine the frequency of adverse outcomes and pool the survival after TAVI in frail patients.
• The strengths of this review are the comprehensive literature search strategy and inclusion of frail patients from randomized controlled trials and observational studies.
• This review will exclude studies in which frailty was assessed without reference to a method of frailty assessment.
INTRODUCTION
Research on the benefits of transcatheter aortic valve implantation (TAVI) compared to surgical aortic valve replacement (SAVR) and medical management is ongoing, however it has been recognized that some patient populations fail to benefit from TAVI. 1 With increasing economic and clinical implications of TAVI, better understanding of how patient factors impact survival, functionality, complications, and quality of life remains a priority. 2 Patients referred for TAVI typically have advanced age and multiple comorbidities, and the prevalence of frailty can be as high as 63%. 3, 4 Frailty is defined as a syndrome of impaired physiological reserve and increased vulnerability to stressors. 5 When exposed to stressors, such as chronic illness and surgery, frail patients are prone to adverse events, procedural complications, prolonged recovery, functional decline, and mortality. 6 Although multiple studies have shown the value of frailty in predicting patient outcomes after TAVI, there is still a lack of consensus on the best way to assess frailty in clinical practice, with no single standard method of 
METHODS AND ANALYSIS
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Eligibility criteria
Participants: We will include patients with aortic stenosis, diagnosed as frail, who underwent a TAVI procedure. The mean age of the study population will be restricted to 65 years and older. Since the focus of this review is on frailty rather than baseline surgical risk, we will not use baseline surgical risk as exclusion criteria. We anticipate that the majority of studies will include patients at high or intermediate surgical risk.
We will include frail patients whose status had been assessed and measured prospectively using one of the following approaches: a) comprehensive geriatric assessment linked to a frailty index, such as the Rockwood Frailty index, b) a multidimensional frailty index such as the Fried scale, c) a single-item measure of frailty such as gait speed and d) clinical judgement without the use of specific frailty assessment tools. [8] [9] [10] [11] We will consider assessments that are directly measured or self-reported. Since new frailty indices are continually being developed, we will include studies using frailty scores that we have not anticipated.
Some methods of frailty assessment do not have a defined 'frailty threshold'. Studies will be excluded if mean frailty scores are reported without dichotomizing the study population into frail and non-frail groups, or if frailty cut-off points were defined by the study sample (i.e. percentile or median). If different studies use the same frailty measure but use a different cut-off for frailty we will report frailty using the criteria defined by each individual study. 12 If a study reports separately on a 'pre-frail' group, we will not include this data in the frail group.
We will only include studies that intended to measure frailty, even if the method of frailty measurement has been newly developed. If studies do not specify the method of frailty measurement, we will search the original protocol or cited references for the method used to measure frailty. Studies will be excluded if a method of frailty assessment is not referenced. We will not consider studies that used either comorbidity or disability alone as a marker of frailty, since these are related but distinct factors, 13 however we will consider studies where comorbidity or disability are measured as part of a multidimensional frailty assessment. Studies will be excluded if baseline frailty status is measured after the TAVI procedure or if the assessment is specifically focused on cognition, nutritional status, mood or mental health symptoms, or social relations or support. If multiple studies originating from the same patient population are found, we will include relevant data from all studies. If multiple frailty measurements were used in one study, we will extract all data, but will incorporate study data into data synthesis once, using the more established, more commonly used frailty measure. Intervention: We will include all forms of TAVI, regardless of procedural approach, types of valves, and type of anesthesia We will exclude studies that investigated the effects of interventions such as health services and rehabilitation programs on patients undergoing TAVI.
Outcome measures:
The primary outcome will be mortality . Secondary outcomes will be clinical outcomes and health-related quality of life. Both utility-based and psychometric measures of quality of life will be included. A complete list of outcome measures is summarized in Table 1 . We will add additional outcomes to the list, if outcomes we have not anticipated are found in the literature.
Types of study:
This review will include any study reporting mortality, clinical outcomes, or quality of life in patients meeting frailty criteria. We will include non-comparative cohorts of patients undergoing TAVI who have been diagnosed with frailty and comparative cohorts of frail and non-frail patients undergoing TAVI in which outcomes are reported separately for frail patients. In studies of comparative cohorts, only data in the frail cohorts will be extracted.
Studies with sample size of fewer than 20 frail patients will be excluded. We will include data from randomized controlled trials (RCTs) in which patients were randomized to TAVI or SAVR, if outcomes are reported separately by treatment and frailty status.
Information sources
A systematic search strategy will be employed to identify published, unpublished, and ongoing studies. We will search the online database PubMed, EMBASE, PsycINFO, Cochrane Library, Web of Science and ClinicalTrial.gov for articles published in 2006 or later. A search of conference abstracts will be performed on relevant conferences held in the last three years. In the search strategy, the publication language will not be limited as study authors have the ability to 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
read articles published in multiple languages. We will also search the reference lists of articles and relevant reviews identified in the search for any additional studies. Search strategies for each database will be reported and a PRISMA flow diagram presented.
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Search strategy
The specific search strategies for each database will be developed by an information specialist with experience conducting systematic reviews. The research team will provide input and feedback into the development of the strategy. A draft search strategy for EMBASE is given in Table 2 . This strategy will be adapted for other databases.
Data management
We will use Covidence online software to manage data. The title and abstract of all articles identified in the search will be uploaded to Covidence for abstract screening. Full text articles will be uploaded for further screening and reasons for exclusion will be noted at the full text review stage. All included articles will be allocated a unique study ID code to track articles throughout the data screening and extraction process. Data extraction and quality appraisal will be managed in Microsoft Excel.
Selection process
Two reviewers will independently review all abstracts identified in the initial search, and studies meeting the inclusion criteria will be included for full-text review. Full-text review of articles will be performed independently by two reviewers. Disagreement will be resolved by a third reviewer.
Data collection process
We plan to use a standardized data collection form constructed in Microsoft Excel. Data will be extracted by one reviewer and independently audited by another reviewer. Disagreements will 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
be resolved by obtaining consensus between the two reviewers or consultation with a third reviewer when necessary. We will attempt to contact study authors to obtain missing data.
Reasons for missing data and how each study dealt with missing data will be recorded.
Data Items
The data collection form will include a list of fields given in Table 2 . If any information is not reported, this will be recorded in the corresponding field. If two or more studies present
Kaplan-Meier curves with time to death we will collect this data. If the numbers are not directly available, we will digitize the curves to retrieve patient level time to event data.
15
Risk of bias in individual studies
or "low risk" of bias in the following domains: study population, study attrition, prognostic factor measurement, outcome measurement, study confounding, and statistical analysis and reporting. 16 For our research purpose, we will not consider the study confounding and model development strategy sections of the tool as we anticipate they will not apply to the types of studies we will be reviewing.
Data synthesis
We will categorize clinical outcomes and report the frequency at each time point in tabular form. We will group results reported at similar times into pre-specified periods of interest. For example, results reported at 4-weeks and 8-weeks may be grouped with results at 6-weeks. For continuous outcomes we will report the mean value and standard deviation.
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Primary outcomes: For all studies, we will abstract the number of deaths and the median follow-up time to calculate the mortality rate per 100 person-years. We will pool mortality from multiple studies and model the death rate using a meta-analysis based on the Poisson distribution. 17 For studies reporting mortality, we will perform a meta-analysis of the odds of deaths at 30 days and 12 months, respectively. A single pooled Kaplan-Meier curve of time to death will be reproduced and presented by reconstructing the time to death data from individual studies.
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Clinical outcomes: For time-to-event outcomes, if studies present Kaplan-Meier curves with time to myocardial infarction, stroke, bleeding complications, acute kidney injury, vascular complications, conduction disturbances, new pacemaker implantation, repeat coronary or valvular intervention, neurocognitive dysfunction, delirium, and readmission, we will use the same methods described above to collect the information on numbers at risk and total number of events, and then create a single pooled Kaplan-Meier curve for each clinical outcome. If studies do not report time to event data, we will extract the number of events and the median follow-up time to calculate the event rate per 100-person years. Event rates from multiple studies will be pooled using a meta-analysis based on the Poisson distribution. For post-procedure length of hospitalization, we will pool data from multiple studies using a meta-analysis of the mean length of hospitalization.
Quality of life measures:
When two or more studies report mean quality of life using the same measures at baseline and the same follow-up time point, we will pool mean scores to analyze changes in quality of life. We will calculate the mean change in quality of life along with the standard deviation (SD), from baseline (T 1 ) to the follow-up time point (T 2 ), using the formula ୭୪ ଶି୭୪ ଵ ୗୈ ଶ . When two or more studies report mean quality of life at baseline and the . 18 We will report the standardized change scores for each time point and pool the standardized change scores from each study using random effects model. If studies measure quality of life using the SF-36, and report the mean mental component score (MCS) and the mean physical component score (PCS) separately, we will pool MCS and PCS separately.
Assessment of heterogeneity
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Sub-group analyses
Sensitivity analyses
We will perform sensitivity analyses to test if the findings are robust. If studies have a wide range of quality, we will exclude low quality studies from sensitivity analysis. If there is a wide range of definitions of frailty, we may also perform sensitivity analysis on the basis of frailty measure.
Meta-regression
Meta-regression will be performed to further investigate the potential source of clinical heterogeneity and to determine the influence of age, frailty (continuous variable), and quality of life measurements on outcomes if we obtain sufficient data. 20 Prevalence of frailty will be calculated by averaging the percentage of patients with its reported prevalence. The metareg function (STATA 14.0) will be used to undertake meta-regression with log-risk estimates and the standard error will be determined from 95% confidence intervals for the log-risk estimates.
Patient and Public Involvement statement:
Discussion
Frailty is increasingly being recognized as an important prognostic indicator to predict poor outcomes in patients undergoing TAVI procedures. Green et al analyzed data from the PARTNER (Placement of AoRtic TraNscathetER Valves) Trial and found that frailty was associated with increased mortality and a higher risk of poor outcome 1 year after TAVR. 21 Further to this, Zajarias et al evaluated patients in the PARTNER II randomized trial and demonstrated higher 30 day and 1 year mortality in frail patients. 22 However, since most studies have focused on improving surgical risk prediction, more research centered on patient outcomes and quality of life are needed. 23 While frailty has been identified as an important concept, there is a lack of consensus in the literature on how it should be assessed, and that makes the field of study challenging. In this regard, Dent et al. reviewed the definitions and quality of more than a dozen frailty measurements used in research and clinical practice. 8 In a systematic review, Kim et al.
identified 13 frailty instruments and evaluated their ability to predict negative outcomes in patients undergoing TAVI. 23 The FRAILTY-AVR study found that within the same cohort of TAVI patients assessed with seven different frailty tools, the prevalence of frailty ranged from 35-74% depending on the frailty tool. 24 With this review, we aim to summarize the frailty methods being used in TAVI patients, describe the domains of frailty being assessed in each study, and synthesize prognostic information. Our goal is to help move the field of frailty measurement in TAVI toward greater consensus.
Our review has several strengths. We will perform a comprehensive literature search to identify both published and unpublished studies, our search will include RCTs and observational studies, as well as references from previous reviews. Furthermore, two reviewers will independently use the QUIPS tool to assess the risk of bias and we will use GRADE to assess the quality of included studies. To the best of our knowledge, this will be the first review to investigate the frequency of adverse outcomes and to pool estimates of survival after TAVI in frail patients from multiple studies.
Our study also has some limitations. While many frailty assessments are similar in identifying frailty, different methods of frailty assessment cannot be assumed to be interchangeable. 25, 26 Although we will perform sub-group analysis by type of frailty measure to account for these differences, the pooled results may be subject to heterogeneity. In addition, while we will perform sub-group analysis by type of frailty assessment, we do not anticipate being able to adjust for domains of frailty in our analysis. Our study will characterize prognosis for frail patients undergoing TAVI, and we will not compare prognosis to other groups of patients or treatments. While this provides a focused synthesis, interpretation of the results will occur in the context of previously conducted systematic reviews of TAVI and will be somewhat subjective. We expect to encounter studies that applied multiple frailty instruments in the same patient group and in this situation we will only extract data from one frailty instrument and this may introduce selection bias. Finally, some studies may define an intermediate "pre-frail" state.
Though less vulnerable than the frail group, pre-frail patients are at higher risk than robust patients for experiencing adverse outcomes. 27, 28 We may not find sufficient data to synthesize outcomes for this important sub-group.
With increased uptake of TAVI, the goal of our study to better understand how frailty impacts survival, functionality, complications, and quality of life is of great clinical importance. 2 Clinical practice guidelines recommend assessing frailty as one component of risk when considering heart valve procedures for patients. 29 The literature describes a number of different frailty measures capable of improving risk prediction in TAVI patients, suggesting that frailty assessment will help identify patients most likely to benefit from TAVI. ,30 Pre-procedural frailty assessment can help identify potentially modifiable factors that may improve outcomes for frail patients. 31 Research into the impact of pre-operative interventions to improve outcomes for frail patients are ongoing but preliminary studies have demonstrated positive impacts on surgical outcomes of frail people. We believe the results of this review will inform clinicians, patients, and health care administrators, of the best available evidence about the impact of frailty in patients undergoing TAVI. We also expect that our findings will fill certain gaps, as well as trigger further research to enhance clinical decision making with a focus on patient-important outcomes.
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